Mechanisms and Novel Therapeutics in Pulmonary Hypertension
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 44
Special Issue Editor
Interests: vascular remodeling; microvasculopathy; pulmonary hypertension; high flow stress; CTEPH; macrophage; catheter intervention
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pulmonary hypertension (PH) is a severe condition characterized by elevated blood pressure in the pulmonary arteries due to various reasons, leading to right heart failure and high mortality rates if treatment is delayed.
PH research has moved from a focus on idiopathic causes to a broader understanding that involves a variety of etiologies, including drug treatment of pulmonary arterial hypertension (PAH), catheter intervention in thromboembolic disease, and the aging patient population and associated patients with cardiopulmonary comorbidities due to advances in treatment. Although treatment has progressed, the etiology is not fully clarified in some types of PH.
This Special Issue aims to explore recent advancements in PH diagnosis, treatment, and mechanistic insights, fostering collaboration and innovation in the field.
We will spotlight the latest developments in imaging techniques and biomarkers for early diagnosis, genetic research, therapeutic interventions, and basic research with a focus on identifying the etiology of PH and improving patient outcomes, including quality of life.
We welcome comprehensive reviews, original research articles, and clinical perspectives addressing challenges in medical care (drug therapy and intervention therapy), comorbidity management, and emerging therapeutic approaches in PH.
Dr. Shun Minatsuki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary hypertension
- vascular remodeling
- genetic study
- vascular remodeling (microvasculopathy)
- medical and interventional treatment
- cardiopulmonary comorbidity
- prognosis
- quality of life
